---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-24-000085"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2024-06-24T23:59:59+00:00"
generated_at: "2026-06-01T02:27:51.251492+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Recursion gives guidance on seven clinical readouts within ~18 months and Bayer LOWE partnership

## Summary
- Topline Phase 2 data for REC-994 (CCM) in Sep 2024; prelim Phase 2 data for REC-2282 (NF2) in Q4 2024.
- REC-3964 (C. diff) Phase 2 start Q4 2024; RBM39 IND Q3 2024; Target Epsilon IND early 2025.
- Bayer first beta-user of LOWE platform; joint oncology project towards Lead Series nomination; 25 data packages Q3 2024.
- ADME industrialization ~90x throughput over manual; genome-scale transcriptomics knockout map; 90% success predicting compound failures.

## SEC filing metadata
- accession: 0001601830-24-000085
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2024-06-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000085/0001601830-24-000085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000085/rxrx-20240624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-24-000085
- JSON: https://secwatch.observer/filing/0001601830-24-000085.json
- Plain text: https://secwatch.observer/filing/0001601830-24-000085.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.